Results 161 to 170 of about 2,071,500 (370)
Multiple drug resistant tuberculosis. [PDF]
Journal of Clinical Pathology, 1997 Francis Drobniewski, M Yates
openaire +3 more sources
Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression
Molecular Oncology, EarlyView.Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park +6 more
wiley +1 more source
A Model for Emergence of Multiple Anti-Microbial Resistance in a Petri Torus [PDF]
arXiv, 2017 This work introduces a new statistical physics lattice model of bacteria interacting with anti-microbial drugs that can reproduce qualitative features of resistance emergence and whose model parameters and outputs can be measured with controlled \textit{in vitro} experiments. The lattice is inhabited by agents modeled by Ising perceptrons.
arxiv
Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance
Molecular Oncology, EarlyView.Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren +4 more
wiley +1 more source
CHANGES IN THE PREVALENCE OF DRUG RESISTANT TUBERCULOSIS
Туберкулез и болезни лёгких, 2017 The tendency of tuberculosis prevalence reduction observed in the Russian Federation is mostly related to the cases without multiple drug resistance (MDR).
V. B. Galkin +3 more
doaj +1 more source
Slowing evolution is more effective than enhancing drug development for managing resistance [PDF]
arXiv, 2013 Drug resistance is a serious public health problem that threatens to thwart our ability to treat many infectious diseases. Repeatedly, the introduction of new drugs has been followed by the evolution of resistance. In principle there are two ways to address this problem: (i) enhancing drug development, and (ii) slowing drug resistance.
arxiv
Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value
Molecular Oncology, EarlyView.The Unsupervised AML Multi‐Omics Classification System (UAMOCS) integrates genomic, methylation, and transcriptomic data to categorize AML patients into three subtypes (UAMOCS1‐3). This classification reveals clinical relevance, highlighting immune and chromosomal characteristics, prognosis, and therapeutic vulnerabilities.
Yang Song +13 more
wiley +1 more source
Fiyz̤, 2017 Background: Acinetobacter baumannii are widely distributed pathogens in hospitals. They have the ability to have various mechanisms of resistance. Multiple drug resistant (MDR) strains of A. baumannii have created therapeutic problems worldwide.
Nahid Madadi-Goli +2 more
doaj
A clinical update on Antibiotic Resistance Gram-negative bacteria in Malaysia- a review [PDF]
Journal of International Pharmaceutical Research, 2018, 2019 Antibiotics are the wonder discoveries to combat microbes. For decades, multiple varieties of antibiotics have been used for therapeutic purposes in hospital settings and communities throughout the world. Unfortunately, bacteria have become resistant to commonly prescribed antibiotics.
arxiv
Molecular Oncology, EarlyView.TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam +9 more
wiley +1 more source